Table 1), with intermediate expression in healthy hematopoietic stem cells (HSCs), and a broad range of expression in most AML cytogenetic subtypes compared to one of its key upstream proteostatic regulation partners SKP2 (Supp. This evidence concerns the gene SKP2 and acute myeloid leukemia.